Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Magnetic Janus micromotors for fluorescence biosensing of tacrolimus in oral fluids

Loading...
Thumbnail Image

Full text at PDC

Publication date

2024

Advisors (or tutors)

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier
Citations
Google Scholar

Citation

Glahn-Martínez, Bettina, et al. «Magnetic Janus Micromotors for Fluorescence Biosensing of Tacrolimus in Oral Fluids». Biosensors and Bioelectronics, vol. 244, enero de 2024, p. 115796. https://doi.org/10.1016/j.bios.2023.115796.

Abstract

Tacrolimus (FK506) is a macrolide lactone immunosuppressive drug that is commonly used in transplanted patients to avoid organ rejection. FK506 exhibits high inter- and intra-patient pharmacokinetic variability, making monitoring necessary for organ graft survival. This work describes the development of a novel bioassay for monitoring FK506. The bioassay is based on using polycaprolactone-based (PCL) magnetic Janus micromotors and a recombinant chimera receptor that incorporates the immunophilin tacrolimus binding protein 1A (FKBP1A) tagged with Emerald Green Fluorescent Protein (EmGFP). The approach relies on a fluorescence competitive bioassay between the drug and the micromotors decorated with a carboxylated FK506 toward the specific site of the fluorescent immunophilin. The proposed homogeneous assay could be performed in a single step without washing steps to separate the unbound receptor. The proposed approach fits the therapeutic requirements, showing a limit of detection of 0.8 ng/mL and a wide dynamic range of up to 90 ng/mL. Assay selectivity was evaluated by measuring the competitive inhibition curves with other immunosuppressive drugs usually co-administered with FK506. The magnetic propulsion mechanism allows for efficient operation in raw samples without damaging the biological binding receptor (FKBP1A-EmGFP). The enhanced target recognition and micromixing strategies hold considerable potential for FK506 monitoring in practical clinical use.

Research Projects

Organizational Units

Journal Issue

Description

Keywords

Collections